Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity
Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity
复制标题
DOI：
10.1086/520816
复制
发表时间：
2007-09-15
影响因子：
6.4
通讯作者：
Boushey, Homer A.
中科院分区：
文献类型：
--
作者：
Kistler, Amy;Avila, Pedro C.;Boushey, Homer A.
背景50%~ 80%的哮喘急性发作与病毒性呼吸道感染（RTI）有关，但由于传统病毒检测方法的范围和通量有限，病毒病原体多样性对哮喘预后的影响尚不清楚。我们研究了病毒芯片（一种基于DNA微阵列的病毒检测平台）在成人哮喘和非哮喘患者RTI中表征病毒多样性的能力。病毒芯片检测病毒的样本比例（65%）比培养分离（17%），同时表现出高一致性（98%）和可比的敏感性（97%）和特异性（98%）病原体特异性聚合酶链反应。在每个患者亚组的RTI中鉴定出相似的病毒谱;然而，发现了人冠状病毒（HCoV）和人鼻病毒（HRV）之间意想不到的多样性。除一株HCoV外，其余均与新发现的HCoV-NL 63和HCoV-HKU 1病毒相对应，共检测到超过20种不同血清型的HRV，其中包括一组5种不同的分离株，形成了一个不同的遗传亚群。病毒芯片可以检测RTIs中存在的病毒病原体的已知和新变体。考虑到这里检测到的多样性，有必要进行更大规模的研究，以确定特定的病毒亚型是否会增加哮喘急性发作的风险。
Background. Between 50% and 80% of asthma exacerbations are associated with viral respiratory tract infections (RTIs), yet the influence of viral pathogen diversity on asthma outcomes is poorly understood because of the limited scope and throughput of conventional viral detection methods.Methods. We investigated the capability of the Virochip, a DNA microarray-based viral detection platform, to characterize viral diversity in RTIs in adults with and without asthma.Results. The Virochip detected viruses in a higher proportion of samples (65%) than did culture isolation (17%) while exhibiting high concordance (98%) with and comparable sensitivity (97%) and specificity (98%) to pathogen-specific polymerase chain reaction. A similar spectrum of viruses was identified in the RTIs of each patient subgroup; however, unexpected diversity among human coronaviruses (HCoVs) and human rhinoviruses (HRVs) was revealed. All but one of the HCoVs corresponded to the newly recognized HCoV-NL63 and HCoV-HKU1 viruses, and >20 different serotypes of HRVs were detected, including a set of 5 divergent isolates that formed a distinct genetic subgroup.Conclusions. The Virochip can detect both known and novel variants of viral pathogens present in RTIs. Given the diversity detected here, larger-scale studies will be necessary to determine whether particular substrains of viruses confer an elevated risk of asthma exacerbation.